Seizert Capital Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Seizert Capital Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-152,428	Closed	-$5.11M	–	222
2016 Q4	$5.11M	Buy	152,428 +238	+0.2%	+$6.82K	0.18%	76
2016 Q3	$4.05M	Sell	152,190 -12,661	-8%	-$294K	0.15%	77
2016 Q2	$3.63M	Buy	164,851 +47,060	+40%	+$1.23M	0.14%	83
2016 Q1	$3.46M	Buy	117,791 +17,640	+18%	+$491K	0.12%	101
2015 Q4	$3.31M	Buy	100,151 +5,693	+6%	+$186K	0.1%	118
2015 Q3	$3.41M	Buy	94,458 +10,853	+13%	+$466K	0.1%	114
2015 Q2	$3.76M	Buy	+83,605	New	+$3.25M	0.1%	114

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

MCM

Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Seizert Capital Partners's ENTA Position: Q1 2017 in Review

Seizert Capital Partners sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 152,428 shares — an estimated $5.11M sold.

Seizert Capital Partners first reported a position in ENTA in Q2 2015 and held it in 7 quarters. The position peaked at $5.11M in Q4 2016. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

Seizert Capital Partners reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Seizert Capital Partners sold 152,428 Enanta Pharmaceuticals shares in Q1 2017, an estimated $5.11M.
Seizert Capital Partners first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Seizert Capital Partners's Enanta Pharmaceuticals position peaked at $5.11M in Q4 2016.
126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Seizert Capital Partners's 13F filing for Q1 2017, filed 10 May 2017.